Related references
Note: Only part of the references are listed.Effects of the fibroblast activation protein inhibitor, PT100, in a murine model of pulmonary fibrosis
Christine Egger et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2017)
FAP positive fibroblasts induce immune checkpoint blockade resistance in colorectal cancer via promoting immunosuppression
Lingling Chen et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2017)
FGF21-receptor agonists: an emerging therapeutic class for obesity-related diseases
Junichiro Sonoda et al.
HORMONE MOLECULAR BIOLOGY AND CLINICAL INVESTIGATION (2017)
Circulating FGF21 proteolytic processing mediated by fibroblast activation protein
Eugene Y. Zhen et al.
BIOCHEMICAL JOURNAL (2016)
Fibroblast Activation Protein (FAP) Accelerates Collagen Degradation and Clearance from Lungs in Mice
Ming-Hui Fan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2016)
OPLS3: A Force Field Providing Broad Coverage of Drug-like Small Molecules and Proteins
Edward Harder et al.
JOURNAL OF CHEMICAL THEORY AND COMPUTATION (2016)
Fibroblast activation protein predicts prognosis in clear cell renal cell carcinoma
Jose I. Lopez et al.
HUMAN PATHOLOGY (2016)
Fibroblast Activation Protein Cleaves and Inactivates Fibroblast Growth Factor 21
Diana Ronai Dunshee et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2016)
RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis
Peter Brunker et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Biomarkers of intestinal fibrosis - one step towards clinical trials for stricturing inflammatory bowel disease
Paolo Giuffrida et al.
UNITED EUROPEAN GASTROENTEROLOGY JOURNAL (2016)
Human FGF-21 Is a Substrate of Fibroblast Activation Protein
Andrew L. Coppage et al.
PLOS ONE (2016)
Lower serum fibroblast activation protein shows promise in the exclusion of clinically significant liver fibrosis due to non-alcoholic fatty liver disease in diabetes and obesity
K. H. Williams et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2015)
Extended Structure Activity Relationship and Pharmacokinetic Investigation of (4-Quinolinoyl)glycy1-2-cyanopyrrolidine Inhibitors of Fibroblast Activation Protein (FAP)
Koen Jansen et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
The Prognostic Significance of Cancer-Associated Fibroblasts in Esophageal Squamous Cell Carcinoma
Sang Yun Ha et al.
PLOS ONE (2014)
Increased Expression of CCN2, Epithelial Membrane Antigen, and Fibroblast Activation Protein in Hepatocellular Carcinoma with Fibrous Stroma Showing Aggressive Behavior
Gi Jeong Kim et al.
PLOS ONE (2014)
Quantitation of fibroblast activation protein (FAP)-specific protease activity in mouse, baboon and human fluids and organs
Fiona M. Keane et al.
FEBS OPEN BIO (2014)
Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments
G. Madhavi Sastry et al.
JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN (2013)
Identification of Selective and Potent Inhibitors of Fibroblast Activation Protein and Prolyl Oligopeptidase
Sarah E. Poplawski et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Increased N-terminal cleavage of alpha-2-antiplasmin in patients with liver cirrhosis
S. Uitte De Willige et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2013)
Activatable Near-Infrared Fluorescent Probe for In Vivo Imaging of Fibroblast Activation Protein-alpha
Jinbo Li et al.
BIOCONJUGATE CHEMISTRY (2012)
Expression of fibroblast activation protein in human pancreatic adenocarcinoma and its clinicopathological significance
Min Shi et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2012)
Fibroblast Activation Protein Expression in Crohn's Disease Strictures
Laura Rovedatti et al.
INFLAMMATORY BOWEL DISEASES (2011)
Enhancement of fibrinolysis by inhibiting enzymatic cleavage of precursor α2-antiplasmin: a rebuttal
E. . Agusti-Cobos et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2011)
Enhancement of fibrinolysis by inhibiting enzymatic cleavage of precursor α2-antiplasmin
K. N. Lee et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2011)
Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice
Angelica M. Santos et al.
JOURNAL OF CLINICAL INVESTIGATION (2009)
Fibroblast activation protein and chronic liver disease
Xin Maggie Wang et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2008)
Phase II trial of single agent Val-boroPro (Talabostat) inhibiting fibroblast activation protein in patients with metastatic colorectal cancer
Kalyani Narra et al.
CANCER BIOLOGY & THERAPY (2007)
Clinical implications of fibroblast activation protein in patients with colon cancer
Leonard R. Henry et al.
CLINICAL CANCER RESEARCH (2007)
Selective inhibition of fibroblast activation protein protease based on dipeptide substrate specificity
CY Edosada et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Peptide substrate profiling defines fibroblast activation protein as an endopeptidase of strict Gly2-Pro1-cleaving specificity
CY Edosada et al.
FEBS LETTERS (2006)
Fibroblast activation protein:: a serine protease expressed at the remodeling interface in idiopathic pulmonary flbrosis
PS Acharya et al.
HUMAN PATHOLOGY (2006)
Binding kinetics and duration of in vivo action of novel prolyl oligopeptidase inhibitors
JI Venäläinen et al.
BIOCHEMICAL PHARMACOLOGY (2006)
Antiplasmin-cleaving enzyme is a soluble form of fibroblast activation protein
KN Lee et al.
BLOOD (2006)
Novel procedure for modeling ligand/receptor induced fit effects
W Sherman et al.
JOURNAL OF MEDICINAL CHEMISTRY (2006)
Fibroblast activation protein alpha is expressed by chondrocytes following a pro-inflammatory stimulus and is elevated in osteoarthritis
JM Milner et al.
ARTHRITIS RESEARCH & THERAPY (2006)
Fibroblast activation protein is expressed by rheumatoid myofibroblast-like synoviocytes
Stefan Bauer et al.
ARTHRITIS RESEARCH & THERAPY (2006)
Structural and kinetic analysis of the substrate specificity of human fibroblast activation protein α
K Aertgeerts et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
A cyclopent-2-enecarbonyl group mimics proline at the P2 position of prolyl oligopeptidase inhibitors
EM Jarho et al.
JOURNAL OF MEDICINAL CHEMISTRY (2004)
Electrostatic environment at the active site of prolyl oligopeptidase is highly influential during substrate binding
Z Szeltner et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Structural basis of proline-specific exopeptidase activity as observed in human dipeptidyl peptidase-IV
R Thoma et al.
STRUCTURE (2003)
Proyl peptidases: a serine protease subfamily with high potential for drug discovery
JS Rosenblum et al.
CURRENT OPINION IN CHEMICAL BIOLOGY (2003)
Structures of prolyl oligopeptidase substrate/inhibitor complexes -: Use of inhibitor binding for titration of the catalytic histidine residue
V Fülöp et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Targeted disruption of mouse fibroblast activation protein
J Niedermeyer et al.
MOLECULAR AND CELLULAR BIOLOGY (2000)
Share Paper
